Pharmacologic Management of Spasticity Following Stroke
Open Access
- 1 October 2004
- journal article
- review article
- Published by Oxford University Press (OUP) in Physical Therapy
- Vol. 84 (10) , 973-981
Abstract
Spasticity is a pervasive and debilitating condition that frequently occurs following upper motor neuron (UMN) lesions. Although the exact incidence of spasticity is unknown, it is likely that it affects more than half a million people in the United States alone, and more than 12 million people worldwide.1 Following stroke, approximately 65% of individuals develop spasticity.2Keywords
This publication has 67 references indexed in Scilit:
- Spasticity: A Rehabilitation Challenge in the ElderlyGerontology, 2001
- The Prevention and Management of Complications After StrokePhysical Medicine and Rehabilitation Clinics of North America, 1999
- Gabapentin for the treatment of spasticity in patients with spinal cord injurySpinal Cord, 1997
- Traditional pharmacological treatments for spasticity part II: General and regional treatmentsMuscle & Nerve, 1997
- Spasticity After StrokeDrugs & Aging, 1996
- CLONIDINE IN THE TREATMENT OF BRAINSTEM SPASTICITYAmerican Journal of Physical Medicine & Rehabilitation, 1992
- Management of SpasticityAmerican Journal of Physical Medicine & Rehabilitation, 1988
- A multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegiaCurrent Medical Research and Opinion, 1988
- Antispasticity drugs: Mechanisms of actionAnnals of Neurology, 1985
- Neurophysiologic mechanisms and neuroanatomic substrates related to spasticityNeurology, 1978